In vitro study of the effect of romidepsin on fluconazole againgst Candida albicans

Abstract

Abstract:

Objective To investigate the influence of romidepsin on fluconazole's antifungal activities to Candida albicans in vitro. Methods A total of 15 C. albicans strains were studied. Susceptibility of fluconazole with or without different concentrations romidepsin was determined according to the CLSI microdilution method M27-A3. Results The tested strains included five fluconazole sensitive strains, five dose-dependent strains and five resistant strains. The inhibition of romidepsin (2 μg/mL and 4 μg/mL) markedly reduced the MIC, the trailing growth and the growth of most C. albicans strains. Conclusions Romidepsin has enhancing effect on fluconazole against C. albicans in vitro and can inhibit the tailing growth of fluconazole.

Key words: Candida albicans, histone deacetylase inhibitors, fluconazole, romidepsin, resistance

CLC Number:

R379.4

CAI Qing, YANG Lian-juan, GAO Zhi-qin, REN Hong-jin, YANG Hong, TAN Jing-wen. In vitro study of the effect of romidepsin on fluconazole againgst Candida albicans[J]. Chinese Journal of Mycology, 2019, 14(4): 200-203,216.

References

[1] Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis:species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study[J]. J Clin Microbiol,2018, 56(7):e00577-18.
[2] Sharma SV, Lee DY, Li B,et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1):69-80.
[3] Morschhäuser J. Regulation of multidrug resistance in pathogenic fungi[J]. Fungal Genet Biol, 2010,47(2):94-106.
[4] Smith WL,Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals:correlation with reduction in CDR and ERG upregulation[J]. Antimicrob Agents Chemother, 2002, 46(11):3532-3539.
[5] Li X, Cai Q, Mei H, et al. The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans[J]. J Antimicrob Chemother, 2015, 70(7):1993-2003.
[6] Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:Approved Standard M27-A3[S]. CLSI, Wayne, PA, USA, 2008.
[7] Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts:Fourth Informational Supplement M27-S4[S]. CLSI, Wayne, PA, USA, 2012.
[8] Suzuki MM, Bird A. DNA methylation landscapes:provocative insights from epigenomics[J]. Nat Rev Genet, 2008, 9(6):465-476.
[9] Yang XJ,Seto E. The Rpd3/Hda1 family of lysine deacetylases:from bacteria and yeast to mice and men[J]. Nat Rev Mol Cell Biol, 2008, 9(3):206-218.
[10] Chung CG,Poligone B. Cutaneous T cell lymphoma:an update on pathogenesis and systemic therapy[J]. Curr Hematol Malig Rep, 2015, 10(4):468-476.
[11] Li Y, Chen K, Zhou Y, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor[J]. Curr Cancer Drug Targets, 2015, 15(6):493-503.
[12] Pfaller MA, Messer SA, Georgopapadakou N,et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens[J]. J Clin Microbiol, 2009, 47(12):3797-3804.
[13] Prince HM, Dickinson M,Khot A. Romidepsin for cutaneous T-cell lymphoma[J]. Future Oncol, 2013, 9(12):1819-1827.
[14] Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma:prolonged stable disease provides clinical benefits for patients in the pivotal trial[J]. J Hematol Oncol, 2017, 10(1):154.
[15] Furumai R, Matsuyama A, Kobashi N, et al. FK228(depsipeptide) as a natural prodrug that inhibits class I histone deacetylases[J]. Cancer Res, 2002, 62(17):4916-4921.